Avalo Therapeutics is a clinical stage biotechnology company based in Rockville, MD, specializing in the development of therapies targeting the LIGHT-signaling network to treat immune dysregulation. They focus on reducing LIGHT levels to moderate immune dysregulation in various acute and chronic inflammatory disorders.
With a pipeline of high value potential first-in-class biologics, Avalo Therapeutics aims to address dysregulated inflammation through the LIGHT-signaling network, which includes the immunoregulatory cytokine LIGHT and its signaling receptors HVEM and lymphotoxin receptor. Their innovative approach is driven by a deep understanding of the disease-driving mechanism in autoimmune and inflammatory reactions in barrier organs.
Generated from the website